Respire_final-01
  • CORPORATE
    • Company Overview
    • Board of Directors
    • RespireRx Organization Structure
    • Social Media Guidelines
  • NEUROTRANSMISSION
  • RESOLUTIONRX
    • Cannabinoid Platform Summary
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • ENDEAVOURRX
    • Neuromodulators
    • Ampakines
      • AMPAkine Platform Summary
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
    • GABAkines
      • GABAkines Platform Summary
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

RespireRx Pharmaceuticals Inc. is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.

In the News

2/1/23 – ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits

February 1, 2023j3ff1

1/23/23 – RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois

January 23, 2023j3ff1

1/12/23 – RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform

January 23, 2023j3ff1
All News

WATCH: RespireRx CFO Jeff Margolis Shares Updates on the Company’s Creation of Australian Subsidiary

Watch

WATCH: RespireRx CFO Jeff Margolis Discusses New Letter of Intent with Australian CRO

Watch

©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.